ResMed | RMD - Ebitda


ResMed reported $559.78M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Ansell USD 185.8M 7M Dec/2025
Artivion USD 22.72M 1.84M Dec/2025
AtriCure USD 27.28M 10.21M Jun/2026
Baxter International USD 474M 165M Jun/2026
Cochlear AUD 306.4M 13.5M Dec/2025
Cooper Companies USD 67.9M 255.5M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Dexcom USD 388.7M 24.2M Jun/2026
Edwards Lifesciences USD 555.6M 485.5M Mar/2026
Fisher Paykel Healthcare NZD 434M 70M Jun/2026
Globus Medical USD 279.84M 48.01M Jun/2026
Haemonetics USD 96.17M 91.87M Jun/2026
Idexx Laboratories USD 468.46M 67.59M Jun/2026
Insulet USD 199.8M 18.1M Jun/2026
Integra LifeSciences USD 79.79M 1.37M Sep/2026
Intuitive Surgical USD 1.2B 147.7M Jun/2026
Medtronic USD 2.63B 174M Jun/2026
Philips EUR 910M 343M Jun/2026
Ramsay Health Care AUD 1.12B 10.6M Dec/2025
ResMed USD 559.78M 9.06M Jun/2026
Sigma Healthcare AUD 19.96M 5.15M Jul/2024
Sonic Healthcare AUD 839.07M 51.09M Dec/2024
Steris USD 443M 48.3M Mar/2026
Teleflex USD 122.91M 47.28M Jun/2026
Thermo Fisher Scientific USD 3.79B 244M Sep/2026